[go: up one dir, main page]

WO2006125181A3 - Derives piperidiniques: utilisation comme agents therapeutiques - Google Patents

Derives piperidiniques: utilisation comme agents therapeutiques Download PDF

Info

Publication number
WO2006125181A3
WO2006125181A3 PCT/US2006/019566 US2006019566W WO2006125181A3 WO 2006125181 A3 WO2006125181 A3 WO 2006125181A3 US 2006019566 W US2006019566 W US 2006019566W WO 2006125181 A3 WO2006125181 A3 WO 2006125181A3
Authority
WO
WIPO (PCT)
Prior art keywords
stearoyl
piperidine derivatives
coa desaturase
desaturase modulators
modulators
Prior art date
Application number
PCT/US2006/019566
Other languages
English (en)
Other versions
WO2006125181A2 (fr
Inventor
Jianmin Fu
Vishnumurthy Kodumuru
Shifeng Liu
Original Assignee
Xenon Pharmaceuticals Inc
Jianmin Fu
Vishnumurthy Kodumuru
Shifeng Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc, Jianmin Fu, Vishnumurthy Kodumuru, Shifeng Liu filed Critical Xenon Pharmaceuticals Inc
Publication of WO2006125181A2 publication Critical patent/WO2006125181A2/fr
Publication of WO2006125181A3 publication Critical patent/WO2006125181A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'invention concerne des méthodes de traitement d'une maladie ou d'un état pathologique véhiculé par la stéaryle-CoA désaturase (SCD) chez un mammifère, de préférence un humain. Ces méthodes consistent à administrer au mammifère un composé de formule (I); formule dans laquelle p, G, J, L, M, W, R2, R3, R4 et R5 sont tels que définis dans la description. L'invention concerne par ailleurs des compositions pharmaceutiques qui contiennent les composés de formule (I).
PCT/US2006/019566 2005-05-19 2006-05-19 Derives piperidiniques: utilisation comme agents therapeutiques WO2006125181A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68246505P 2005-05-19 2005-05-19
US60/682,465 2005-05-19

Publications (2)

Publication Number Publication Date
WO2006125181A2 WO2006125181A2 (fr) 2006-11-23
WO2006125181A3 true WO2006125181A3 (fr) 2007-03-29

Family

ID=37432189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/019566 WO2006125181A2 (fr) 2005-05-19 2006-05-19 Derives piperidiniques: utilisation comme agents therapeutiques

Country Status (1)

Country Link
WO (1) WO2006125181A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050124A1 (fr) * 2005-05-19 2007-05-03 Xenon Pharmaceuticals Inc. Derives fusionnes de piperidine et leurs utilisations en tant qu'agents therapeutiques
KR20090040478A (ko) 2006-08-24 2009-04-24 노파르티스 아게 ２-(피라진-２-일)-티아졸 및 ２-(１Ｈ-피라졸-３-일)-티아졸 유도체, 및 대사, 심혈관 및 기타 장애의 치료를 위한 스테아로일-ＣｏＡ 데새투라제(ＳＣＤ) 억제제로서의 관련 화합물
TW200826936A (en) 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AR064965A1 (es) 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
US8575167B2 (en) 2007-02-06 2013-11-05 Takeda Pharmaceutical Company Limited Spiro compounds having stearoyl-CoA desaturase action
WO2010094120A1 (fr) 2009-02-17 2010-08-26 Merck Frosst Canada Ltd. Nouveaux composés spiro utiles comme inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
EP2459568A4 (fr) 2009-07-28 2013-02-27 Merck Frosst Canada Ltd Nouveaux composés spiro utiles en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
KR20140084164A (ko) 2011-10-15 2014-07-04 제넨테크, 인크. 암의 치료를 위한 scd1 길항제
JP6293127B2 (ja) 2012-05-22 2018-03-14 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド 未分化細胞の選択的阻害剤
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
BR112019013954A2 (pt) 2017-01-06 2020-02-11 Yumanity Therapeutics, Inc. Métodos para o tratamento de distúrbios neurológicos
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
SG11202009280RA (en) 2018-03-23 2020-10-29 Yumanity Therapeutics Inc Compounds and uses thereof
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011657A2 (fr) * 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Derives de piperazine et utilisation comme agents therapeutiques
WO2005042542A1 (fr) * 2003-10-31 2005-05-12 Otsuka Pharmaceutical Co., Ltd. Composes 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole pour le traitement de la tuberculose

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011657A2 (fr) * 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Derives de piperazine et utilisation comme agents therapeutiques
WO2005042542A1 (fr) * 2003-10-31 2005-05-12 Otsuka Pharmaceutical Co., Ltd. Composes 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole pour le traitement de la tuberculose

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRAHN, M.S. ET AL.: "Radiation-induced polymerization monitored in situ by time-resolved fluorescence of probe molecules in methyl methacrylate", NUCLEAR INSTRUMENTS AND METHODS IN PHYSICS RESEARCH B, vol. 208, 2003, pages 405 - 410, XP002411451 *
HUANG T L ET AL: "Synthesis and anti-Pneumocystis carinii activity of piperidine-linked aromatic diimidazolines", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 6, no. 17, 1996, pages 2087 - 2090, XP002227683, ISSN: 0960-894X *
LAUTESLAGER, X.Y. ET AL.: "Conformational dynamics of charge-transfer states in donor-bridge-acceptor systems", EUR. J. ORG. CHEM., vol. 16, 2001, pages 3105, XP002411450 *
SCHERER T ET AL: "Synthesis and exploratory photophysical investigation of donor-bridge-acceptor systems derived from N-substituted 4-piperidones", RECUEIL DES TRAVAUX CHIMIQUES DES PAYS-BAS, ELSEVIER SCIENCE PUBLISHERS. AMSTERDAM, NL, vol. 112, no. 10, October 1993 (1993-10-01), pages 535 - 548, XP002087998, ISSN: 0165-0513 *

Also Published As

Publication number Publication date
WO2006125181A2 (fr) 2006-11-23

Similar Documents

Publication Publication Date Title
WO2006125181A3 (fr) Derives piperidiniques: utilisation comme agents therapeutiques
WO2007130075A8 (fr) Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
WO2007046867A3 (fr) Derives de piperidine et leurs utilisations comme agents therapeutiques
WO2007044085A3 (fr) Composes heteroaryle et leurs utilisations en tant qu'agents therapeutiques
WO2007136746A3 (fr) Composés macrocycliques et leurs utilisations en tant qu'agents thérapeutiques
WO2007046868A3 (fr) Derives de thiazolidine et leurs utilisations en tant qu’agents therapeutiques
EP2266569A3 (fr) Dérivés hétérocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
EP2269610A3 (fr) Dérivés hétérocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
WO2006086447A3 (fr) Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
MX2007003327A (es) Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
WO2006034315A3 (fr) Derives heterocycliques et utilisation de ceux-ci comme agents therapeutiques
WO2007138472A3 (fr) Dérivés de la triazolopyridazine
TW200626153A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2005011657A3 (fr) Derives de piperazine et utilisation comme agents therapeutiques
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200624427A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626155A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2007061360A3 (fr) Nouveau composes
WO2006086562A3 (fr) Derives de phenylazetidinone
WO2006125194A3 (fr) Derives de piperazine et leurs utilisations en tant qu'agents therapeutiques
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2006125178A3 (fr) Composes de pyridazine tricycliques et leurs utilisations comme agents therapeutiques
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
WO2006100081A3 (fr) Derives d'indoxyle substitues, medicaments les contenant et leur utilisation

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06770730

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06770730

Country of ref document: EP

Kind code of ref document: A2